Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

428 Results

Guidelines and Advice

Systemic Treatment Emergency Preparedness Guidance Document

Status: Current

Updated

Aug 2025

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 2

Updated

Sep 2025

Guidelines and Advice

Role of Adjuvant Treatment in Resected Pancreatic Ductal Adenocarcinoma

Status: Current
ID: GL 2-33
Version: 2

Jun 2025

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Jan 2025

Guidelines and Advice

An Endorsement of the 2025 Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the EOTTD, ESGO, GCIG, ISSTD

Status: Current
ID: GL END 4-19

Updated

Nov 2025

Guidelines and Advice

Recommendations for the Safe Use and Handling of Oral Anti-Cancer Drugs (OACDs) in Community Pharmacy: A Pan-Canadian Consensus Guideline

Status: Current
ID: GL-C50-30

Feb 2017

Guidelines and Advice

Guidance on the Substitution of Systemic Therapy Agents

Status: Current
ID: GL-C50-33
Version: 1

Aug 2017

Drug

durvalumab

Other Name(s): Imfinzi®

Quick Link(s):

Drug Monograph, Patient Info Sheet

May 2025

Guidelines and Advice

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Status: Archived
ID: GL-7-A-2016-3

Apr 2017

Guidelines and Advice

Use of Preoperative Chemotherapy With or Without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer

Status: Archived
ID: 7-4
Version: 2

Dec 2017

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2025

Pages